Literature DB >> 26738865

Expression of SRPK1 in gliomas and its role in glioma cell lines viability.

Ioanna Sigala1, Konstantinos I Tsamis2, Anna Gousia3, George Alexiou2,4, Spyridon Voulgaris4, Thomas Giannakouros1, Athanassios P Kyritsis2, Eleni Nikolakaki5.   

Abstract

Among factors regulating the splicing of major importance is serine/arginine protein kinase 1 (SRPK1) that phosphorylates SR splicing factors. SRPK1 is expressed in the mammalian central nervous system in a region- and neuron-specific manner. Based on previous observations that glial cells are practically devoid of SRPK1 and reports showing aberrant expression of SRPK1 in numerous tumors, but with conflicting roles, this study aims to investigate the expression of SRPK1 in glioma and its influence on tumor cell biological features. As shown by immunohistochemical analysis, malignant glioma cells express SRPK1 in glioblastomas with significant association between SRPK1 expression and patients' survival. SRPK1 expression was also significantly upregulated at the messenger RNA (mRNA) and protein level in glioma cell lines. Small interfering RNA-mediated downregulation of SRPK1 had little effect on cell viability, while it slightly enhanced the sensitivity of cells to killing by cisplatin. These results support the idea that at least in vitro, the effect of SRPK1 knockdown on the viability of glioma cell lines is rather limited, while the in vivo effects could be attributed to the modulation of angiogenesis by SRPK1.

Entities:  

Keywords:  5-FU; Cell viabilty; Chemotherapeutic agents; Cisplatin; Gliomas; SRPK1

Mesh:

Substances:

Year:  2016        PMID: 26738865     DOI: 10.1007/s13277-015-4738-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  26 in total

1.  Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells.

Authors:  F Wang; J Zhou; X Xie; J Hu; L Chen; Q Hu; H Guo; C Yu
Journal:  Neoplasma       Date:  2015       Impact factor: 2.575

2.  Serological identification of adult T-cell leukaemia-associated antigens.

Authors:  Masakatsu Hishizawa; Kazunori Imada; Tomomi Sakai; Maki Ueda; Toshiyuki Hori; Takashi Uchiyama
Journal:  Br J Haematol       Date:  2005-08       Impact factor: 6.998

Review 3.  Glioblastoma: pathology, molecular mechanisms and markers.

Authors:  Kenneth Aldape; Gelareh Zadeh; Sheila Mansouri; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2015-05-06       Impact factor: 17.088

4.  SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line.

Authors:  P W Schenk; A W Boersma; J A Brandsma; H den Dulk; H Burger; G Stoter; J Brouwer; K Nooter
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

5.  SRPK1: a cisplatin sensitive protein expressed in retinoblastoma.

Authors:  Subramanian Krishnakumar; Adithi Mohan; Mallikarjuna Kandalam; Hema L Ramkumar; Nalini Venkatesan; Radha R Das
Journal:  Pediatr Blood Cancer       Date:  2008-02       Impact factor: 3.167

Review 6.  Splicing in oncogenesis and tumor suppression.

Authors:  Daisuke Kaida; Tilman Schneider-Poetsch; Minoru Yoshida
Journal:  Cancer Sci       Date:  2012-07-24       Impact factor: 6.716

Review 7.  The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance.

Authors:  Peter Bouwman; Jos Jonkers
Journal:  Nat Rev Cancer       Date:  2012-09       Impact factor: 60.716

8.  SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt.

Authors:  Bo Zhou; Yandong Li; Qing Deng; Haixiao Wang; Yuping Wang; Bing Cai; Ze-Guang Han
Journal:  Mol Cell Biochem       Date:  2013-05-06       Impact factor: 3.396

9.  Elevated expression of the serine-arginine protein kinase 1 gene in ovarian cancer and its role in Cisplatin cytotoxicity in vitro.

Authors:  Kunle Odunsi; Paulette Mhawech-Fauceglia; Christopher Andrews; Amy Beck; Olajumoke Amuwo; Shashikant Lele; Jennifer D Black; Ruea-Yea Huang
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

10.  Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.

Authors:  M V Gammons; R Lucas; R Dean; S E Coupland; S Oltean; D O Bates
Journal:  Br J Cancer       Date:  2014-07-10       Impact factor: 7.640

View more
  10 in total

1.  Knockdown of DIXDC1 Inhibits the Proliferation and Migration of Human Glioma Cells.

Authors:  Jianguo Chen; Chaoyan Shen; Jinlong Shi; Jianhong Shen; Wenjuan Chen; Jie Sun; Shaocheng Fan; Yuanqi Bei; Peng Xu; Hao Chang; Rui Jiang; Lu Hua; Bin Ji; Qingfeng Huang
Journal:  Cell Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.046

2.  Variety and Dynamics of Proteoforms in the Human Proteome: Aspects of Markers for Hepatocellular Carcinoma.

Authors:  Stanislav Naryzhny; Victor Zgoda; Artur Kopylov; Elena Petrenko; Olga Kleist; Аlexander Archakov
Journal:  Proteomes       Date:  2017-11-23

3.  The GAUGAA Motif Is Responsible for the Binding between circSMARCA5 and SRSF1 and Related Downstream Effects on Glioblastoma Multiforme Cell Migration and Angiogenic Potential.

Authors:  Davide Barbagallo; Angela Caponnetto; Cristina Barbagallo; Rosalia Battaglia; Federica Mirabella; Duilia Brex; Michele Stella; Giuseppe Broggi; Roberto Altieri; Francesco Certo; Rosario Caltabiano; Giuseppe Maria Vincenzo Barbagallo; Carmelina Daniela Anfuso; Gabriella Lupo; Marco Ragusa; Cinzia Di Pietro; Thomas Birkballe Hansen; Michele Purrello
Journal:  Int J Mol Sci       Date:  2021-02-07       Impact factor: 5.923

Review 4.  Serine-Arginine Protein Kinase 1 (SRPK1): a systematic review of its multimodal role in oncogenesis.

Authors:  William P Duggan; Emer O'Connell; Jochen H M Prehn; John P Burke
Journal:  Mol Cell Biochem       Date:  2022-05-18       Impact factor: 3.842

5.  A Novel Splice Variant of BCAS1 Inhibits β-Arrestin 2 to Promote the Proliferation and Migration of Glioblastoma Cells, and This Effect Was Blocked by Maackiain.

Authors:  Yun-Hua Kuo; Huey-Shan Hung; Chia-Wen Tsai; Shao-Chih Chiu; Shih-Ping Liu; Yu-Ting Chiang; Woei-Cherng Shyu; Shinn-Zong Lin; Ru-Huei Fu
Journal:  Cancers (Basel)       Date:  2022-08-11       Impact factor: 6.575

6.  Identification of the key immune-related genes in aneurysmal subarachnoid hemorrhage.

Authors:  Xing Wang; Dingke Wen; Chao You; Lu Ma
Journal:  Front Mol Neurosci       Date:  2022-09-12       Impact factor: 6.261

7.  Impaired expression of serine/arginine protein kinase 2 (SRPK2) affects melanoma progression.

Authors:  Mônica Maria Magalhães Caetano; Gabriela Alves Moreira; Maria Roméria da Silva; Gabriela Rapozo Guimarães; Leandro de Oliveira Santos; Amanda de Ambrósio Pacheco; Raoni Pais Siqueira; Flávia Carneiro Mendes; Eduardo De Almeida Marques Da Silva; Abelardo Silva Junior; Juliana Lopes Rangel Fietto; Ângela Saito; Mariana Boroni; Gustavo Costa Bressan
Journal:  Front Genet       Date:  2022-09-23       Impact factor: 4.772

8.  COL3A1 and SNAP91: novel glioblastoma markers with diagnostic and prognostic value.

Authors:  Yuan-Feng Gao; Xiao-Yuan Mao; Tao Zhu; Chen-Xue Mao; Zhi-Xiong Liu; Zhi-Bin Wang; Ling Li; Xi Li; Ji-Ye Yin; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Oncotarget       Date:  2016-10-25

Review 9.  Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives.

Authors:  Ilias P Nikas; Sophie C Themistocleous; Stavroula A Paschou; Konstantinos I Tsamis; Han Suk Ryu
Journal:  Cells       Date:  2019-12-19       Impact factor: 6.600

10.  Nuclear Translocation of SRPKs Is Associated with 5-FU and Cisplatin Sensitivity in HeLa and T24 Cells.

Authors:  Ioanna Sigala; Maria Koutroumani; Anastasia Koukiali; Thomas Giannakouros; Eleni Nikolakaki
Journal:  Cells       Date:  2021-03-30       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.